Loading
A phase 1/2 trial of fOLFIRI (5-FU, leucovorin, irinotecan), cetuximab, panitumumab, gemcitabine and other drugs in colorectal cancer, run by Institut de Recherches Internationales Servier, now recruiting.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies is a phase 1/2, interventional study registered as NCT05786924 by Institut de Recherches Internationales Servier, with a registry enrolment figure of 554 participants, started 2023-04-18 and due to reach its primary completion in 2028-06. Interventions recorded: S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D. Primary outcome: Dose Escalation: Incidence of dose-limiting toxicities (DLTs); Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Optimization/Expansion: Objective response (OR). Colorectal eligibility wording from the registry: "* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations". Sites: Australia, China, Denmark, France, Hong Kong, Italy, Japan, Spain, United Kingdom, United States. United Kingdom sites listed: 3. No results are recorded here; the registry entry is the source.
Shares Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag colorectal-deep-dive.